{"id":"W2171889601","doi":"10.1016/s0140-6736(15)60125-8","title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","year":2015,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":831,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"National Institute for Health and Care Research; Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Etanercept; Placebo; Psoriasis; Psoriasis Area and Severity Index; Internal medicine; Clinical trial; Blinding; Interleukin 17; Physical therapy; Dermatology; Psoriatic arthritis; Cytokine; Tumor necrosis factor alpha; Secukinumab; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002839913,0.001894046,0.00538083,0.0004502443,0.0003578736,0.001710997,0.001161544,0.002735218,0.005520692],"category_scores_gemma":[0.002648519,0.0007780574,0.00480062,0.0004455791,0.001172335,0.001765526,0.0004591041,0.004025876,0.0008070294],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008961141,"about_ca_system_score_gemma":0.0007120431,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001222353,"about_ca_topic_score_gemma":0.001684387,"domain_scores_codex":[0.9989491,0.0005045334,0.0001007396,0.0001865848,0.00009173516,0.000167303],"domain_scores_gemma":[0.9986675,0.0006821236,0.0002827274,0.00008718792,0.00006062401,0.0002198415],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9802157,0.0009203554,0.0002499099,0.001378357,0.002230678,0.00002909388,0.00003587023,0.0002044127,0.0009735191,0.0001105772,0.0005327106,0.0131187],"study_design_scores_gemma":[0.9740138,0.02206123,0.001201496,0.0001072851,0.00142069,0.00003668578,0.00002835195,0.000169556,0.0001644323,0.0002379118,0.0005434373,0.00001519281],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.90271,0.08164968,0.001572615,0.002618151,0.002694692,0.002044612,0.001904434,0.0002230677,0.004582708],"genre_scores_gemma":[0.9714415,0.01791836,0.001410995,0.001881125,0.001093908,0.001353001,0.001124042,0.00004603324,0.003731018],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005520692,"threshold_uncertainty_score":0.01846856,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1149020683539135,"score_gpt":0.3566539598176311,"score_spread":0.2417518914637176,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}